![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Guerbet SA | EU:GBT | Euronext | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 38.80 | 37.25 | 42.00 | 0.00 | 06:30:05 |
€397.7 million at constant exchange rates, up 5.6%
Satisfactory activity growth
Villepinte, July 27, 2017 - Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is publishing revenue of €407.1 million for the 1st half-year of 2017, up 8.1% at current exchange rates and 5.6% at constant exchange rates (CER). In the second quarter, published revenue stood at €204.0 million, up 5.7% at current exchange rates and 3.8% at CER.
Consolidated Group revenue (IFRS)
In millions of euros at June 30 | Change (%) | 2017 at current exchange rates | Change (%) | 2017 at constant exchange rates | 2016 published |
Sales in Europe | +0.6% | 190.9 | +1.6% | 192.8 | 189.7 |
Sales in Other Markets | +15.6% | 216.2 | +9.6% | 204.9 | 187.0 |
Total 1st half-year revenue | +8.1% | 407.1 | +5.6% | 397.7 | 376.7 |
After a successful year in 2016, focused on turning around the declining ex-CMDS business, Guerbet's revenue for the first half-year of 2017 grew both in Europe and the Other Markets. This positive development has come despite the gradual withdrawal of certain products, which is already under way, as part of the recently announced plan to streamline Guerbet's product range. This includes products such as Oxilan® and Hexabrix® in X-Ray imaging, and Optimark® in MRI.
In Europe, in the second quarter, the revenue at current exchange rates for the zone rose by 0.1% to €96.6 million.
The exchange rate effect for Other Markets resulted in a €11.3 million gain. Aside from this positive impact, the increase in revenue was mainly due to sales in Asia, and especially China, in the US and in Latin America. Sales at current exchange rates were up 11.3% at €107.4 million for Other Markets over the quarter.
At constant exchange rates, activity over the first half-year breaks down as follows:
Activity growth in 2017
Guerbet would like to note two recent changes to the regulations and its competitive environment:
These two factors will have opposite effects - one negative, the other positive - on the Group's activity in the MRI segment.
Given how difficult it is to assess these effects, the Group will not provide precise annual guidance. As the first half-year was satisfactory, however, Guerbet is maintaining its revenue and EBITDA growth target for fiscal year 2017.
Upcoming events:
Publication of the 2017 half-yearly consolidated accounts
September 26, 2017, after trading
About Guerbet
Guerbet is a pioneer in the contrast agents field with over 90 years' of experience and is one of the leaders in medical imaging worldwide. It offers a full range of pharmaceutical products, medical devices and services for X-ray (XR) and Magnetic Resonance Imaging (MRI) scanners and for Interventional Radiology and Theranostics (IRT) to improve the diagnosis and treatment of patients. With 7% of its revenue and more than 200 employees dedicated to R&D, Guerbet invests heavily in research and innovation. Guerbet (GBT) is listed on Euronext Paris (Segment B - Mid Caps) and generated €776 million in revenue in 2016. For more information about Guerbet, visit www.guerbet.com
For more information about Guerbet, please visit www.guerbet.com
Contacts
Guerbet | Actifin |
Jean-François Le Martret Chief Financial Officer +33 (0)1 45 91 50 00 | Financial Communications Benjamin Lehari +33 (0)1 56 88 11 25 blehari@actifin.fr Press Jennifer Jullia +33 (0)1 56 88 11 19 jjullia@actifin.fr |
1 Year Guerbet Chart |
1 Month Guerbet Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions